Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report
Published in
International Journal of Radiation Oncology, Biology, Physics, September 2019
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2022.
All research outputs
#24,919,282
of 34,560,275 outputs
Outputs from International Journal of Radiation Oncology, Biology, Physics
#12,204
of 15,721 outputs
Outputs of similar age
#261,012
of 378,773 outputs
Outputs of similar age from International Journal of Radiation Oncology, Biology, Physics
#154
of 261 outputs
Altmetric has tracked 34,560,275 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,721 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,773 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 261 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
